Invenomic Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tanger
SKT
|
+$4.15M |
| 2 |
H&R Block
HRB
|
+$3.78M |
| 3 |
WW
WW International
WW
|
+$2.81M |
| 4 |
First Bancorp
FBP
|
+$2.81M |
| 5 |
Children's Place
PLCE
|
+$2.66M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Stride
LRN
|
+$3.41M |
| 2 |
Nomad Foods
NOMD
|
+$2.58M |
| 3 |
Microsoft
MSFT
|
+$2.45M |
| 4 |
AAWW
Atlas Air Worldwide Holdings, Inc.
AAWW
|
+$2.3M |
| 5 |
eBay
EBAY
|
+$2.06M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 17.14% |
| 2 | Industrials | 10.35% |
| 3 | Financials | 9.48% |
| 4 | Technology | 9.33% |
| 5 | Healthcare | 6.49% |
Similar funds
Invenomic Capital Management's Q3 2020 Portfolio in Review
As of Q3 2020, Invenomic Capital Management held 191 positions worth $182M, up 34% from $135M the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Invenomic Capital Management deployed $40.6M of net new capital in Q3 2020, opening 39 new positions and adding to 42 existing holdings. Its largest new stake was First Bancorp: 504,037 shares worth $2.63M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 17% of assets, up from 17% a quarter earlier, followed by Industrials and Financials.
On the sell side, the largest reduction was Stride, an estimated $3.41M trimmed.
- Invenomic Capital Management's largest Q3 2020 buy was First Bancorp: 504,037 shares worth $2.63M.
- Invenomic Capital Management added most to Tanger in Q3 2020, an estimated $4.15M increase.
- Invenomic Capital Management's biggest Q3 2020 reduction was Stride, cutting an estimated $3.41M.
- Invenomic Capital Management fully exited Microsoft in Q3 2020, selling an estimated $2.45M.
- Invenomic Capital Management's ten largest holdings make up 29% of its $182M portfolio in Q3 2020.
- Invenomic Capital Management opened 39 new positions and closed 50 in Q3 2020.
- Invenomic Capital Management's portfolio value rose 34% quarter-over-quarter to $182M.
Based on Invenomic Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.